Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $20.2857.

ENTA has been the topic of a number of recent research reports. Rodman & Renshaw initiated coverage on shares of Enanta Pharmaceuticals in a report on Thursday, March 26th. They issued a “buy” rating and a $20.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Monday, April 20th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th. Finally, Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Deutsche Bank AG grew its holdings in shares of Enanta Pharmaceuticals by 4.6% during the fourth quarter. Deutsche Bank AG now owns 24,107 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 1,055 shares during the last quarter. Public Employees Retirement System of Ohio grew its holdings in shares of Enanta Pharmaceuticals by 8.3% during the third quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 1,100 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Enanta Pharmaceuticals by 8.3% during the third quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 1,383 shares during the last quarter. AlphaQuest LLC grew its holdings in shares of Enanta Pharmaceuticals by 18.1% during the third quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 1,562 shares during the last quarter. Finally, Quantinno Capital Management LP grew its holdings in shares of Enanta Pharmaceuticals by 4.9% during the first quarter. Quantinno Capital Management LP now owns 35,122 shares of the biotechnology company’s stock valued at $444,000 after buying an additional 1,627 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Price Performance

ENTA stock opened at $13.95 on Friday. Enanta Pharmaceuticals has a 1 year low of $5.55 and a 1 year high of $17.15. The company has a market cap of $405.67 million, a P/E ratio of -5.39 and a beta of 1.01. The firm has a 50-day moving average of $13.57 and a 200 day moving average of $13.66.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.01. The business had revenue of $17.16 million for the quarter, compared to analysts’ expectations of $17.03 million. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. On average, equities research analysts expect that Enanta Pharmaceuticals will post -2.01 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.